Drug resistance, to date, has primarily been attributed to increased drug export or detoxification mechanisms. Despite correlations between drug export and drug resistance, it is increasingly apparent that such mechanisms cannot fully account for chemoresistance in neoplasia. It is now widely accepted that chemotherapeutic drugs kill tumour cells by inducing apoptosis, a genetically regulated cell death programme. Evidence is emerging that the exploitation of survival pathways, which may have contributed to disease development in the first instance, may also be important in the development of the chemoresistance. This review discusses the components of and associations between multiple signalling cascades and their possible contribution to the development of neoplasia and the chemoresistant phenotype. Leukemia (2001) 15, 21-34.
Introduction
Resistance to chemotherapy is a major concern, and a serious limiting factor in the treatment of many neoplasias including leukaemias. Initially responsive to treatment, many disorders become increasingly more drug resistant following primary or subsequent relapses, until inevitably, the elevated concentrations of cytotoxins required to control the disease can no longer be tolerated by the patient. In some situations, the treatment may be perceived as more debilitating than the disease itself. Novel pharmaceutical agents which provide a more specific treatment regimen or increase the efficacy of conventional chemotherapy, without increasing toxicity towards patients, would clearly be of immense clinical benefit.
It is now widely accepted that chemotherapeutic drugs kill tumour cells primarily through the induction of apoptosis. Apoptosis is an internally directed, energy requiring suicide programme, normally activated in response to cellular damage, or following physiological insults such as death receptor ligation 1 or withdrawal of survival signals. 2 In chemosensitive cells, drug-mediated injury is frequently translated into an instruction to initiate the apoptotic cascade. Drug resistance can, therefore, be described as a consequence of failure of tumour cells to engage apoptosis in the presence of cytotoxic drugs. Indeed, many tumours intrinsically resistant to chemotherapy are defective in their ability to activate the apoptotic machinery. Multiple inter-connecting signalling pathways are known to regulate apoptosis, survival and proliferation, including Ras, PI3-kinase/PKB, PKC, the stress-activated protein kinases, the Bcl-2 family and Fas/CD95. Each of these pathways will be discussed in this review, as defects in these pathways can have potentially harmful repercussions over tissue homeostasis, promoting oncogenesis and multidrug resistance.
Previously described mechanisms of drug resistance include expression of members of the ATP-binding cassette (ABC) superfamily of transporter proteins, multidrug resistance-associated protein (MRP), and P-glycoprotein. [3] [4] [5] This family reduces intracellular drug accumulation to sublethal levels, by active drug extrusion from the cell against a concentration gradient. Glutathione S-transferases limit drug-mediated damage by conjoining drugs with reduced glutathione prior to exportation from the cell. 3, 6 The target of many cytotoxins is DNA, therefore increased activity of DNA repair enzymes to minimise inflicted damage, is a further established mechanism of drug resistance. However, despite several studies reporting an association between drug export and drug resistance, it is apparent that such mechanisms cannot be solely responsible for chemoresistance and treatment failure. 7 Drug resistance may also arise following multiple courses of chemotherapy where increasingly drug-resistant or anti-apoptotic clones are positively selected.
Attempts to elucidate and understand drug resistance mechanisms, to date, have primarily focused on cytotoxin export or neutralisation. However, increasing evidence suggests that survival pathways may promote tumour initiation and maintenance. Delineation of the signalling pathways which contribute to disease origin and progression, and the evolution of a drug-resistant phenotype, may allow development of novel pharmacological agents which increase tumour sensitivity to death by conventional cytotoxic drugs. This article reviews current understanding of the contribution of intracellular signalling pathways to survival and neoplasia and how disturbances in a cell's natural ability to initiate the death process limits the killing potential of chemotherapeutic regimes.
Ras
Ras, a G-protein located at the plasma membrane, cycles between a GTP-bound active and a GDP-bound inactive state, in response to growth factor or cytokine interaction with cell surface receptor. 8 Receptor-activated Ras relays extracellular signals through signal transduction pathways, mediating multiple intracellular responses including growth, survival, apoptosis and regulation of the immune response. [9] [10] [11] Ras signalling and conversion between its GTP-and GDP-bound forms is a tightly regulated event, orchestrated primarily by guanine-nucleotide exchange factors (GEFs) 12 and GTPaseactivating proteins (GAPs), 13 positive and negative regulators of Ras, respectively. Ras is one of the most frequently deregulated proteins in leukaemias, estimated to be mutated in at least 30% of cases.
14 In actuality, Ras deregulation is likely to be significantly higher, as deregulation of GEFs or GAPs, overexpression of growth factor receptors, 15 autonomous cytokine production, such as interleukin-1␤, 16 ,17 mutation
Leukemia within the Ras promoter 18 or activation by co-operating oncogenes, such as bcr-abl, 19 may all lead to constitutive signalling of Ras, without mutations in Ras itself. Interestingly, Ras-GAP is localised to chromosome 5 which is frequently deleted in many leukaemias. 20 Moreover, as activated Ras is locked into a GTP-bound state, the requirement for growth factors to initiate Ras signalling cascades is presumably circumvented. Oncogenic Ras signalling influences tumorigenesis, not only due to increased proliferation, but also due to the increased ability of Ras to suppress apoptosis. 9, 11 There remains much controversy as to the precise significance of Ras in leukaemia. The high incidence of Ras mutations in the pre-leukaemic disorder, myelodysplasia, suggests that Ras mutations are an initiating event in leukaemias. 21 Conversely, other reports argue that Ras mutations accumulate only with leukaemic progression. 22 Alternatively, in patients lacking Ras mutations, elevated Ras expression is common, resulting in overactive Ras signalling. 23 Recently, an essential role for oncogenic Ras has been reported for tumour maintenance in vivo. 24 Despite extensive debate, Ras deregulation is accepted as contributing to disease aggression, immune evasion and reduced patient survival. 11 Patients with N-Ras mutations have a poor response to chemotherapy and low remission rates. 25 
Ras and Bcl-2
Ras is reported to up-regulate expression of Bcl-2 and Bcl-XL in an IL-3-dependent haemopoietic cell line. 26 Bcl-2 and Bcl-XL are members of an extended family of apoptotic regulators, distinguished by their ability to protect cells from a multitude of apoptosis inducing stimuli. 27 Bcl-2 and Bcl-XL are frequently overexpressed in many malignancies, correlating with disease aggression, resistance to chemotherapy and reduced patient survival rates. 28, 29 Bcl-2 up-regulation is possibly one of the major mechanisms exploited by Ras to promote survival, and to increase cellular resistance to cytotoxic drug-induced apoptosis.
Ras also lies at the pinnacle of many separate signal transduction pathways 9, 11 ( Figure 1 ). Modifications in Ras signalling would alter each of these downstream kinase cascades, permitting amplification of deregulated signals and potentially inducing oncogenesis.
Ras and Bcr-Abl
The bcr-abl oncogene is generated by the translocation of the c-abl tyrosine kinase gene on chromosome 9 into the bcr gene on chromosome 22. Alternative forms of this chimeric protein are the hallmark of chronic myeloid leukaemia (p210) and acute lymphoblastic leukaemia (p190). Bcr-Abl-positive leukaemias are aggressive and drug-resistant, transformed cells being growth factor independent and resistant to apoptosisinducing stimuli. [30] [31] [32] Interestingly, although Ras aberrations are infrequent in Bcr-Abl-transformed cells, 33 increased levels of active GTP-bound Ras are common, presumably due to direct activation of Ras by Bcr-Abl. 19 Thus, it is likely that Ras signalling considerably contributes to disease aggression and resistance to chemotherapeutic drug-induced apoptosis by recruiting multiple signalling cascades to transduce its oncogenic signals. Furthermore, the downstream effector of Ras, PI3-kinase, is also activated by interaction with Bcr-Abl and is required for Bcr-Abl-mediated leukaemogenesis. 34 
Ras and farnesyltransferase inhibitors
The importance of Ras deregulation in leukaemia and other malignancies is reflected in the development of anti-Ras drugs. Ras is synthesised as an inactive precursor molecule, requiring multiple post-translational modifications prior to achieving biologically active status as a mature protein. The most important of these modifications is prenylation of the precursor Ras protein, catalysed by the enzyme, farnesyltransferase. 35, 36 The three forms of mutated Ras proteins, NRas (commonly associated with haematopoietic neoplasms), Kirsten-Ras (predominantly expressed in pancreatic, colorectal and lung cancer with a prevalence of up to 90%), and HarveyRas normally exist as farnesylated proteins in vivo. 14, 21, 35 Inhibition of the farnesyltransferase enzyme prevents post-translational processing of Ras proteins in a highly selective manner. As pharmaceutical agents, farnesyltransferase inhibitors (FTIs) block Ras processing, signalling and transformation in tumour cell lines without overt toxicity. To date, results are extremely promising showing additive, sometimes synergistic growth suppression of cancer cells in culture and in animal studies when inhibitors are used in combination with chemotherapeutic agents. A number of FTIs are currently entering phase II clinical trials. 35, 37 Intracellular expression of an anti-Ras neutralising antibody has been shown to promote apoptosis and tumour regression in Ras-transformed but not untransformed cells. 38 Furthermore, the human reovirus requires an activated Ras signalling pathway to infect cultured cells and has been shown to induce tumour regression in mice.
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The ERK pathway
Ras activation leads to stimulation of the serine/threonine kinase, Raf (MAP-KKK), which successively phosphorylates and activates the dual specificity protein kinase, MAP-kinase kinase (MEK), and the extracellular signal related kinases, ERK1 and ERK2. Once activated, ERK1 and ERK2 translocate to the nucleus, where they phosphorylate transcription factors such as c-Fos and ELK1, regulating immediate-early gene expression. 40 While an essential role for ERK has been established in proliferation, its importance with regard to survival remains somewhat less conclusive. There are reports of ERKmediated protection against apoptosis following growth factor withdrawal. 41 Signalling cascades capable of enhancing cellular survival could potentially increase resistance to cytotoxic drug-induced apoptosis. However, the contribution of ERK to survival under certain circumstances, was not found to extend to protection from cytotoxin-mediated apoptosis. 42 Interestingly, it is the upstream components of this pathway which appear to have an increased capacity for promoting survival. As previously mentioned, oncogenic Ras up-regulates expression of the anti-apoptotic molecules Bcl-2 and Bcl-XL. 26 Activated Raf can suppress apoptosis in an IL-3-dependent cell line following growth factor withdrawal, 43 possibly mediated by interaction with Bcl-2. 44 Raf is also thought to be functionally regulated by PKB/Akt and PKC and to play a role in the phosphorylation of the pro-apoptotic Bcl-2 family member, Bad. [45] [46] [47] 
PI3-kinase, PKB/Akt and Bad
A prolific quantity of data have established PI3-kinase as an important mediator of survival signals, protecting from mul-
Figure 1
Signalling pathways to and from Ras. Ras deregulation may arise following autocrine growth factor production, Bcr-Abl stimulation, point mutation or dysfunction in the Ras regulators, GEFs and GAPs. Ras mediates growth and survival signals through downstream kinases PI3-kinase/PKB, JNK, PKC and ERK1/2. Ras, PKC and survival pathways up-regulate Bcl-2 expression. PKC also induces Bcl-2 phosphorylation, enhancing its survival promoting capabilities.
tiple apoptosis-inducing stimuli, including growth factor withdrawal and anoikis. 48, 49 PI3-kinase may be stimulated by binding of growth or survival factors to cell surface receptors or by interaction with activated Ras. 50 Interestingly, binding of PI3-kinase to activated Ras leads to a further increase in levels of activated Ras. 51, 52 Activation of PI3-kinase results in the formation of phospholipids, such as phosphatidylinositol triphosphate (PIP3). PIP3 binds to PKB (also known as Akt), the major downstream mediator of PI3-kinase survival signals, instigating translocation to the plasma membrane, where PKB is phosphorylated and activated by another PIP3-activated kinase, PDK1 (PIP3-dependent kinase 1). 53 The PKB family is now known to consist of three closely related proteins, PKB␣, PKB␤ and PKB␥. 54 Activated PKB then phosphorylates the pro-apoptotic Bcl-2 family member, Bad. 55 When phosphorylated, Bad is sequestered by the cytoplasmic protein 14-3-3 and apoptosis is inhibited. Conversely, PKB inhibition leads to Bad dephosphorylation and its release from 14-3-3. Bad is now free to bind and neutralise anti-apoptotic Bcl-2 family members, such as Bcl-2 and Bcl-XL, promoting the induction of apoptosis. 55 The regulation of Bad is becoming increasingly complex with reports that Raf, 46 MAP kinase kinase (MEK), 56 cyclic-AMP-dependent protein kinase (PKA) 57 and the calcium-activated protein phosphatase, calcineurin 58 may all be involved in managing its phosphorylation status. As the functions of PI3-kinase become further elucidated, it is increasingly apparent that signalling alterations can modify multiple downstream effectors, possibly contributing to oncogenesis.
It is likely that many of the effects of deregulated Ras, including chemoresistance, are mediated by PI3-kinase following direct activation by Ras. 50 A study investigating this possibility demonstrated that inhibition of PI3-kinase survival Leukemia signals, with concomitant inhibition of PKB, in the acute myeloid leukaemia (AML)-derived cell line, HL60, which endogenously expresses an activated N-Ras mutation, greatly increased sensitivity to cytotoxic drug-induced apoptosis. 42 Similar findings were reported by a second group, where PI3-kinase inhibition accelerated daunorubicin-induced apoptosis in the monocytic cell line, U937. 59 Deregulated PKB is evident in a variety of tumours, due to PKB overexpression, constitutive activation by oncogenic Ras, or following inactivation of the tumour suppressor, PTEN. 53, 60 It is known that the survival effects of PI3-kinase are mediated through PKB, but until recently the most significant downstream target of PKB was considered to be Bad, linking cytokine-mediated survival with the Bcl-2 family of apoptotic regulators. However, it seemed unlikely that such an important survival pathway should act through a single downstream effector, especially considering that Bad is poorly expressed in haemopoietic and lymphoid tissue as compared to many normal human tissues and other tumour cell lines. 61 Recently, it has become increasingly evident that Bad does not mediate all the effects of PI3-kinase/PKB. The capacity of particular cytokines to promote survival does not always correlate with PKB and Bad phosphorylation. In fact, the relationship between PKB, Bad and survival is cytokine and cell-type specific. 56, 62 Furthermore, Bad does not appear to participate in PI3-kinase-mediated resistance to chemotherapeutic druginduced apoptosis. PI3-kinase inhibition sensitises myeloid leukaemia cells to drug-induced apoptosis, independently of alterations in Bad phosphorylation status or binding to antiapoptotic Bcl-2 family members. 42 Recently, additional targets of PKB have been described, which presumably, in time, will be confirmed as participants in PI3-kinase/PKB-mediated Leukemia drug resistance.
PKB and transcription factors NF-B:
NF-B is a member of the ubiquitously expressed family of Rel-related transcription factors, originally thought to co-ordinate cellular response to infection, stress and injury. However, NF-B is becoming increasingly recognised as an important contributor to cell survival and protection from apoptosis. 63, 64 The mechanisms by which NF-B can regulate such diametrically opposing events continues to be somewhat enigmatic. NF-B exists as hetero-and homo-dimers regulated by the inhibitory molecule, IB (inhibitor of NF-B). Binding of NF-B to IB results in cytoplasmic retention of inactive NF-B. Dissociation of the NF-B/IB complex is initiated by site-specific phosphorylation of IB by upstream IB-kinases, IKK1 and IKK2. Phosphorylation of IB targets it for selective ubiquination and subsequent degradation by proteosomal action. Thus, NF-B is free to translocate to the nucleus and initiate transcription of target genes. IKK1 and IKK2 are themselves phosphorylated and activated by upstream kinases, most likely members of the extended mitogen-activated protein kinase kinase kinase (MAPKKK) family, such as NIK (NF-B-inducing kinase) and MEKK1. NIK and MEKK1 are differentially activated by discrete stimuli, leading to selective IKK1 and IKK2 activation and co-ordinated regulation of NF-B. Differential responses are also achieved through the distinct affinities the NF-B complex demonstrates for DNA binding sites present in the promoters of target genes. This potentially explains the relationship of NF-B with seemingly opposing biological events. [63] [64] [65] The intrigue surrounding NF-B concerns its ability to act as a convergence point for a variety of stimuli, including interleukin-1␤, TNF␣, UV and survival factors, IGF-1 and PDGF. 63, 64, 66 Evidence, to date, does not conclusively establish whether NF-B normally functions as a pro-or as an antiapoptotic factor. NF-B protects from apoptosis through transcription of cytokines, including IL-2, IL-6, IL-8, G-CSF and GM-CSF, 64 the Bcl-2 homologue A1, 67 Bcl-x 68 and the inhibitor of apoptosis (IAP) family. 69 NF-B activation protects from TNF␣, ionising radiation and cytotoxic drug-induced apoptosis. 67, 70, 71 In contrast, NF-B also aids induction of apoptosis following serum starvation, where dominant negative NF-B has a protective effect similar to that of Bcl-2 overexpression. 72 NF-B is required for Fas ligand up-regulation following treatment with DNA damaging agents 73 and transcribes the cell cycle regulators, p53 and c-myc, both of which have been implicated in apoptosis. 64, 74 NF-Bmediated induction of cell cycle arrest may function to provide time for cellular assessment of all incoming signals before determining the fate of the cell. Thus, NF-B activation can have contrasting cellular outcomes depending on the nature of the external signal received.
Recently, an alternative pathway for NF-B regulation was described. PKB associates with and activates IKK, inducing phosphorylation and subsequent targeting of IB for proteosomal degradation in response to PDGF 66 and TNF activation. 75 Thus, NF-B may possibly be the mechanism by which PI3-kinase/PKB promotes resistance to cytotoxic drug-mediated apoptosis. Inhibition of PI3-kinase would prevent IB phosphorylation and degradation, ensuring NF-B retention in the cytoplasm and negation of its protective effects, such as protection from chemotherapy-induced apoptosis. 67, 71 Suppression of the caspases (a family of proteases activated during apoptosis) 76 is associated with a drug-resistant phenotype, possibly by NF-B-mediated IAP expression, which binds and inhibits caspase action. 77, 78 NF-B expression is associated with breast cancer, and may represent a novel therapeutic target in the treatment of cancers with dysfunctional NF-B. 79 
CREB:
The nuclear factor CREB (cAMP-responsive element-binding protein), a component of normal cell cycle machinery is also required for cell survival in certain cell types. 80, 81 Phosphorylation of CREB by protein kinase A (PKA) promotes binding to the co-activator CBP (CREB-binding protein) and formation of the CREB/CBP transcription complex. 81, 82 It has recently been shown that PKB can also phosphorylate CREB following serum stimulation, inducing CREB/CBP complex formation, translocation to the nucleus and transcription of target genes. 83 It is this pathway which is reported to up-regulate expression of the anti-apoptotic protein and Bcl-2 family member, Mcl-1. 84 Mcl-1 is primarily expressed in haematopoietic cells and plays an important role in cytokine-induced viability. 85, 86 Thus, PI3-kinase/PKBmediated CREB activation may also contribute to resistance against cytotoxin-induced death.
Forkhead family:
Insulin receptor-like signalling in C. elegans requires PKB homologue activity to suppress the function of DAF-16, a Forkhead family member. 87 A similar pathway has been delineated in mammalian cells, where PI3-kinase/PKB-mediated phosphorylation of Forkhead transcription factors prevents nuclear translocation by inducing binding to the cytoplasmic protein, 14-3-3. Identified members of this family, regulated by PKB, include FKHRL1, 88 FKHR 89 and AFX. 90 Cytoplasmic retention of these transcription factors is thought to prevent the expression of important death inducing genes, such as Fas ligand. 88 The potential influence of transcription factors on resistance to cytotoxic drug-induced apoptosis is enormous. PKB signalling regulates a number of different transcription factor families, both positively and negatively. Therefore, inhibition of such a critical mediator would have serious repercussions on downstream mediators, determining the final cellular outcome towards life or death.
PKB and caspases
The cysteine proteases, or caspases, are activated following apoptotic insult, destroying and inactivating a multitude of important survival mediators, including the signalling proteins, PKB, Raf-1 and Ras-GAP, 91 the DNA repair-associated enzyme, PARP, and components of the cytoskeleton, including actin, lamin and fodrin. 92 Caspases possess autocatalytic activity and can convert downstream caspases from inactive procaspase zymogen to active caspase, amplifying the death cascade. 76 Moreover, caspase-mediated cleavage of Bcl-2 results in its conversion from an anti-apoptotic to a pro-apoptotic protein. 93 The importance of caspase signalling in apoptosis is further highlighted by a recent report, where chemoresistance in the leukaemic cell line, TUR, was attributed to defects in caspase activation. 77 Procaspase 9 is yet another target for PKB activity. PKBmediated site-specific phosphorylation of procaspase 9 results in defective proteolytic processing of this initiator caspase. 94 Inhibition of PI3-kinase and PKB eliminates this block in pro-caspase 9 processing. As caspases are customarily activated following cytotoxic drug treatment, such treatment in combination with PKB inhibition may lead to synergistic activation of the caspases and potentiation of apoptosis. Indeed, PI3-kinase inhibition enhances processing of caspase 3 in TNF-and Fas-treated, but not untreated cells. 95 
PKB and glycogen synthase kinase 3
Glycogen synthase kinase 3 (GSK3), is also a substrate for PKB action and the first to be identified in vivo.
96 GSK3 phosphorylates glycogen synthase (GS), regulating glycogen synthesis in mammals. Cellular stimulation with insulin or IGF-1 leads to PKB-mediated phosphorylation of GSK3. GSK3 is inactivated by phosphorylation, permitting glycogen synthesis by the no longer inhibited GS.
97 GSK3 is also involved in regulation of a range of other substrates including metabolic enzymes, and transcription factors, CREB, c-Myc and AP1, the regulatory subunit of cyclic-AMP-dependent protein kinase and the translation factor eIF-2B. 96, 98, 99 The importance of GSK3 in chemoresistance has not yet been established. However, considering its regulation by the survival promoting molecule PKB, the role played by GSK3 warrants further investigation.
Following reports establishing PI3-kinase as a contributor of consequence to cytotoxic drug resistance in leukaemia cell lines, most likely through PKB signalling, 42, 59 we have speculated upon the potential contribution of known PKB substrates to this process (Figure 2 ). The importance of PKB signalling to survival is underlined by the finding that PKB is also cleaved and inactivated by caspase action during apoptosis. 91 Recently, new targets of PKB signalling have been established PKB mediates survival through multiple downstream effectors including the transcription factors, NF-B, CREB/CBP and the forkhead family. PKB signalling inhibits processing of pro-caspase 9 to its active conformation. PKB phosphorylates the pro-apoptotic Bcl-2 family member Bad, preventing binding and neutralisation of anti-apoptotic family members. PKB also regulates GSK3 activity, influencing downstream effectors such as CREB.
Leukemia including nitric oxide 100, 101 and presumably more remain to be elucidated. Identification of the specific components of the biochemical pathway, which individually or in combination, mediate PI3-kinase resistance to cytotoxic drug-induced apoptosis, will be an exciting challenge for future forthcoming research.
Protein kinase C (PKC)
The PKC family of serine/threonine protein kinases play an important, yet diverse role in signal transduction, mediating the intracellular effects of many extracellular stimuli including growth factors, hormones and drugs. In responding to these multiple stimuli, PKC activity influences mitogenesis, differentiation, survival and apoptosis. [102] [103] [104] The multiplicity of roles in which PKC is implicated presumably arises from the 11 isoenzymes of which the family is composed. 105 These can be categorised into three groups, the classical or calcium-dependent isoenzymes (PKC ␣, ␤I, ␤II and ␥), the novel or noncalcium-dependent (PKC ␦, ⑀, , and ) and the atypical subgroups (PKC , or ). Each of these subgroups possess structural differences, reflecting differential requirements for cofactors essential for activation. Both the calcium and noncalcium-dependent subgroups require the second messenger diacylglycerol (DAG) as well as membrane-associated phospholipids for activation, while the atypical isoforms are independent of both calcium and DAG. The versatility of PKC action is primarily thought to be due to its activation by DAG, produced by intracellular phospholipid turnover.
102-104
The role of PKC in initiating and/or co-operating in disease progression remains unclear. Downregulation of PKC␤ and up-regulation of PKC⑀ expression are early events in prostate neoplasia, with PKC␣ and PKC also demonstrating enhanced expression. 106 Over-expression of PKC␣ and PKC␤ are associated with a less aggressive breast cancer phenotype. 107 PKC␤ has an anti-oncogenic function in colon cancer cells. 108 Conversely, PKC␤ over-expression contributes to fibroblast transformation. 109, 110 Opposing reports have been published regarding the transforming abilities of PKC␣ in fibroblasts. 111, 112 PKC⑀ is oncogenic in colonic epithelial cells, 113 but although having increased expression in hepatocellular carcinomas, does not appear to be involved in transformation or disease progression. 114 Reports concerning the contribution of individual PKC isoenzymes to oncogenesis are often conflicting, presumably resulting from differential isoenzyme tissue expression, cellular localisation, regulation and function. Increased understanding of the contribution of specific PKC isoenzymes to malignancy would allow targeting of PKC as a potential point of therapeutic intervention. In support of this theory is the recent report that antisense inhibition of PKC␣ can reverse the neoplastic properties of human lung carcinoma cells. 115 
PKC and multidrug resistance
Increased expression and activity of PKC, in particular PKC␣, has been correlated with the development of a multidrugresistant (MDR) phenotype 116 through PKC-mediated phosphorylation of p-glycoprotein. 117 Indeed, there is a strong correlation between PKC and MDR-gene expression in both primary and relapsed state AML. 118 In haematopoietic cells, inhibition of PKC dramatically increases sensitivity to chemotherapeutic drug-induced apoptosis, involving alterations in the phosphorylation status of the anti-apoptotic protein, Bcl-2.
119,120 PKC is considered to be the upstream kinase responsible for Bcl-2 phosphorylation, a post-translational modification essential for maximal anti-apoptotic function. 121, 122 In addition, PKC⑀ has been reported to induce Bcl-2 expression, 123 associated with disease aggression, chemoresistance and poor clinical prognosis. 28, 29 PKC and other interacting pathways PKC may also contribute to neoplasia and chemoresistance, through associations with other signalling molecules. Active PKC and Ras co-operate to promote proliferation and transformation, 124, 125 however, following PKC inhibition, the pathway stimulated by Ras is apoptosis. 125 Both Ras and PKC enhance Bcl-2 expression levels and anti-apoptotic function. 26 ,121 PKB may promote survival by mitochondrial targeting of Raf, in a PKC-dependent manner, inducing Bad phosphorylation and promoting survival. 46 p90RSK signalling also blocks Bad-mediated death through a PKC-dependent pathway. 126 Indeed, PKC itself has also been reported to activate Raf. 47 Thus, several of the effects of Ras and Bcl-2 in leukaemia, such as disease aggression and chemoresistance, may be at least partially mediated by PKC, or rely on PKC activity as a co-operating lesion. Furthermore, PKC contributes to Bcr-Abl-mediated drug resistance. 127 Induction of PKC protects from Fas-mediated apoptosis in viral infected T cells. 128 PKC is critical for NF-B activation, by inducing dissociation from IB. 129 As described earlier, NF-B exerts a survival signal and may contribute to chemoresistance. Certain PKC isoforms may be regulated by PI3-kinase through PDK-1. 130 Thus, considering the relationship between PKC, MDR, Bcl-2 and multiple signalling molecules, PKC inhibition may potentially be of immense importance in treatment regimens, augmenting the cytotoxicity of chemotherapeutic drugs and potentiating the killing efficacy of death pathways, such as Fas/CD95. The combinatorial activity of PKC and multiple signalling pathways may also significantly influence cell viability, providing yet another point of therapeutic intervention.
Stress-activated protein kinases
The stress-activated protein kinases (SAPK) or c-jun N-terminal kinases (JNK), a subgroup of the mitogen-activated protein (MAP) kinase family, are involved in the cellular response to toxins, physiological stresses, inflammatory cytokines, DNA damage and heat shock. 131, 132 Upon receipt of extracellular stress, JNK is phosphorylated and activated, in turn phosphorylating and activating c-Jun, a member of the dimeric transcription factor, AP-1. Other AP-1 components include cFos and ATF2. Both ATF2 and c-Fos, in addition to c-Jun are phosphorylated and activated by JNK. 133 c-Fos may also be activated by ERK in response to mitogenic stimulation. 134 A considerable debate regarding the requirement for JNK in the apoptotic cascade is currently being contested. Substantial evidence has implicated JNK and c-Jun as essential components of the apoptotic cascade. Activation of c-Jun is required for apoptosis following NGF withdrawal in neuronal cells 41, 135 and following growth factor withdrawal from IL-6-and IL-2-dependent lymphoid cell lines. 136 Recently, JNK activity was found to be a necessary requirement for UV-induced apoptosis in primary murine embryonic fibroblasts, modulating cytochrome-c release from the mitochondria. 137 Conversely, apoptosis proceeds unhindered in c-Fos/c-Jun null mouse embryos, indicating that AP-1 is a non-essential component of the death cascade. 138 Furthermore, thymocytes lacking an upstream component of the JNK pathway, SEK1, are more susceptible to Fas-mediated apoptosis arguing a protective function for JNK. 139 Interestingly, the same SEK1 mutation did not affect apoptosis in embryonic stem cells or T cells. 139 The role of JNK in Fas-mediated apoptosis is also controversial with opposing reports regarding the requirement for JNK. Several studies suggest that JNK is critical for Fasinduced apoptosis, involved in up-regulating Fas ligand in T cells, 140 neuronal cells 141 and epithelial cells. 142 However, substantial evidence suggests that JNK is non-essential for Fasmediated apoptosis in haemopoietic cell lines. 143, 144 Thus, in certain situations, JNK activity is a positive event in the induction of apoptosis, but in alternative situations and cell types, c-Jun inhibits apoptosis and contributes to proliferation or differentiation. 131, 132 Therefore, cell type 139 and inducing stimulus 145 appear to determine whether JNK activation is a causal or secondary event in apoptosis.
The final biological outcome mediated by JNK activity appears dependent on the state of activation or inactivation of other signalling pathways within the cell. Moreover, JNK activity may be recessive to survival pathway signalling. 41 JNK, like many other signalling molecules seems to exert many varied and sometimes opposing functions, including transformation, growth and development, death and survival. 131, 132 While JNK participation is considered essential for neuronal cell apoptosis, 135 its importance in haematopoietic cells remains less straightforward. Ras activates JNK following IL-3 stimulation, 146 and JNK is essential for Ras 147 and BcrAbl-mediated transformation. 148 It is also required for the induction of apoptosis in lymphocytes. 136 Furthermore, JNK 27 has been associated with chemoresistance, where cells lacking JNK activity are refractory to cytotoxic drug-induced apoptosis. 149, 150 However, in sensitive cells, JNK triggers DNA damaging drug-induced apoptosis by activating the caspase cascade. 150 Thus, JNK may determine the clinical response of tumour cells to cytotoxic therapies. The influence of JNK depends not only on cell type 139 and external stimulus, 145 but also on the activation status of other regulatory signalling pathways. Indeed, the chosen route towards life or death frequently depends on the shift in balance between JNK and ERK signalling. 41, 151, 152 Furthermore, oncogenic Ras is a potent inducer of AP-1. 147 As deregulated AP-1 expression can initiate neoplastic transformation, AP-1 may be a critical Ras effector, contributing to malignancy and chemoresistance.
The Bcl-2 family of apoptotic regulators
The anti-apoptotic protein, Bcl-2, was first recognised for its involvement in the t(14;18) chromosomal translocation, associated with extensive Bcl-2 over-expression in B cell lymphomas. 153 Bcl-2 is also distinguished for its capacity to promote cellular survival rather than proliferation, and to protect against almost all known apoptosis-inducing stimuli, including cytotoxic drugs, growth factor withdrawal, c-myc, radiation, heat and in some cases death receptor activation.
154-159
The related anti-apoptotic Bcl-2 family member, Bcl-XL also confers a drug-resistance phenotype. 160 To date, 17 mammalian homologues of Bcl-2 have been described acting as either anti-(Bcl-XL, Mcl-1, A1, Bcl-w and Boo) or pro-apoptotic proteins (Bax, Bak, Bok, Bik, Blk, Hrk, BNIP3, Bim, Bad, Bid, Bcl-Xs and Diva). 27, 161, 162 Bcl-XL and Bcl-Xs arise through alternative mRNA splicing from the same gene. 163 Bcl-2 has been found at inappropriately high levels in half of all human cancers, 164 frequently in the absence of gene rearrangements, including non-Hodgkin's lymphoma, 165 acute leukaemias 28, 166 and breast cancer, 167 suggesting a fundamental role for Bcl-2 in carcinogenesis. Bcl-2 is particularly significant in AML, where drug resistance becomes increasingly prevalent with disease progression. Bcl-2 is expressed in over 87% of AML cases at presentation, increasing to 100% at relapse. 168 AML blasts also display autocrine growth factor production, up-regulating Bcl-2 expression and increasing resistance to treatment-induced apoptosis. 169 Thus, Bcl-2 potentiates cell survival, contributes to cancer initiation, correlates with disease aggression and chemoresistance and is overall a poor prognostic marker for successful treatment, patient survival and clinical outcome. 28, 168, [170] [171] [172] [173] Transfection of Bcl-2 or Bcl-XL into cell lines greatly increases resistance to numerous insults, including cytotoxic drug-induced apoptosis. 154, 155, 160 Conversely, inhibition or abatement of Bcl-2 function using antisense oligonucleotides reverses chemoresistance, 174, 175 as does elevation of Bcl-2 antagonists, Bax and Bcl-Xs. 176, 177 Furthermore, attenuated Bax expression behaves similarly to increased Bcl-2 expression, augmenting resistance to apoptotic stimuli and enhancing tumour aggression. 178 Thus, the relative balance between pro-and anti-apoptotic molecules appears to determine the overall cellular survival advantage or disadvantage. 179 Initially, it was suggested that the Bcl-2 family exerted their effects by heterodimerisation, resulting in neutralisation of one of the binding partners. 180 However, recent reports have challenged the dogma of heterodimerisation, determining that there exists both heterodimerisation-dependent and -independent mechanisms for the regulation of apoptosis. Hsu et Leukemia al 181 reported that Bax heterodimerisation was an artefact of non-ionic detergent perturbation. Another report determined that while the Bcl-2/Bax heterodimer could promote apoptosis, protection correlated, not with heterodimerisation levels, but rather with the levels of unbound Bcl-2. 182 The survival mechanism employed by the Bcl-2 homologues, A1 and Bcl-w, only partially correlates with dimerisation. 183 Bcl-XL also regulates apoptosis by heterodimerisation-dependent and -independent mechanisms. 184 
Bcl-2 and signalling pathways
Survival factors have been reported to inhibit apoptosis by maintaining intracellular Bcl-2 expression levels. 185 It is likely that these survival factor-regulated kinase cascades also regulate Bcl-2 phosphorylation status, where PKC-mediated phosphorylation is considered essential for optimum anti-apoptotic activity. 121, 122 Phosphorylation may also influence interactions between the Bcl-2 family and targets such as the apoptosis activating factor, Apaf-1. Bcl-XL binding to Apaf-1 is thought to inhibit pro-caspase 9 processing. 186 However, a recent publication has disputed this theory, having found no evidence of interaction between anti-apoptotic family members and Apaf-1. 187 Bcl-2 family members have also been suggested to act at the level of the mitochondria regulating release of the apoptosis promoting factor, cytochrome c, required for Apaf-1 processing of pro-caspase 9.
188,189 Bcl-2 functionally cooperates with Raf to suppress apoptosis, possibly by targeting Raf to the mitochondria, inducing subsequent Bad phosphorylation and inhibition of apoptosis.
44,46
Bcl-2 and p53
Elevated Bcl-2 expression may also be related to loss of p53 function, prevalent in over 50% of cancers. 190, 191 p53 directs cell cycle arrest following DNA damage, and initiates DNA repair when possible prior to further replication. However, following excessive DNA damage, apoptosis is promoted. 192, 193 Functional p53 not only acts as a repressor of Bcl-2 gene expression, but also promotes transactivation of Bax. 194 Thus, loss of p53 not only disables a cells intrinsic mechanism to survey damage, but may also dramatically alter the anti-to pro-apoptotic ratio of Bcl-2 family proteins.
Although the mechanisms of action of Bcl-2 family members remain to be clarified, their anti-and pro-apoptotic capabilities remain undisputed and are unlikely to arise from a single function, but rather a composite of those previously mentioned. Interference with Bcl-2 function or elevation of Bcl-2 antagonist levels, removes an important barrier for the successful progression of apoptosis, and efficient induction of chemotherapeutic drug-induced death. However, attempts to predict clinical outcome based on Bcl-2 studies alone may not be accurate, as individual malignancies exhibit aberrations in specific Bcl-2 family members, influencing chemoresistance and final disease prognosis.
Fas/APO-1/CD95
The cell surface death receptor, Fas/APO-1/CD95 transduces apoptotic signals upon activation by specific death ligands, such as agonistic Fas antibody or under physiological conditions by interaction with cognate Fas ligand. 195 Fas is a Leukemia member of the extended tumour necrosis factor (TNF) superfamily of death receptors and plays an important role in normal physiology. 195 The binding of cognate interacting ligands induces oligomerisation of Fas receptor and the recruitment of signalling molecules, Fas-associated death domain (FADD) and pro-caspase 8 to its cytoplasmic death domains, which together are known as the death-inducing signalling complex or DISC. 195 Initiation of the caspase cascade results in subsequent cell death by either mitochondrial or non-mitochondrial pathways. 159 Bcl-2 can inhibit mitochondrial apoptosis downstream of the DISC. 196 The significance of the Fas death system in chemotherapeutic drug-induced apoptosis is currently the subject of conflicting discussion. Chemotherapeutic drugs have been reported to up-regulate Fas ligand expression on Fas-expressing leukaemia cells. 197 Apoptosis is then triggered by subsequent binding of Fas ligand to Fas receptor. Similar scenarios have also evolved in non-leukaemic tumours, including hepatoblastoma and neuroblastoma. [198] [199] [200] Chemotherapeutic drugs have also been reported to increase sensitivity to Fasinduced apoptosis in both pre-B ALL cells 201 and prostate tumour cells. 202 If Fas involvement in chemotherapy consistently described a successful anti-tumour therapy, it would have far reaching therapeutic consequences. However, publications on Fas involvement in tumours have also illustrated many opposing theories.
While drug-induced up-regulation of Fas on tumour cells would no doubt enhance sensitivity to FasL-positive T cells and NK cells, similar up-regulation of FasL would allow immune evasion, making the tumour immune-privileged and having an injurious effect on the immune system. 195, 203 Indeed, expression of FasL by tumour cells is often accompanied by loss of Fas, thus eliminating the possibility of self-induced apoptosis. 204 There is substantial evidence in support of the viewpoint that cytotoxic drug-induced apoptosis is independent of Fas/Fas ligand recruitment, where blocking the Fas receptor with neutralising antibody fails to inhibit chemotherapeutic drug-induced apoptosis. 205, 206 In acute lymphatic leukaemia cells, although drug-induced apoptosis is associated with increased Fas ligand expression, death appears independent of Fas signalling. 207 Furthermore, analysis of AML patients found no notable differences in Fas expression between patients who achieved complete remission and patients who developed refractory or relapsed AML. 208 Interestingly, Micheau et al 209 report that anti-cancer drugs induce apoptosis by activating the Fas receptor and inducing interaction with FADD, but in a FasL-independent manner. This report may resolve some of the arguments surrounding the necessity of Fas ligand for drug-induced apoptosis. Moreover, in cells expressing Fas antigen, there exists both Fas-dependent and -independent mechanisms of drug-induced apoptosis. 210 It is likely that other intracellular factors such as signalling pathways and anti-apoptotic molecules play an important role in determining final sensitivity to Fas-induced death. An undisputed finding is that synergy between anti-Fas and cytotoxic drug treatment is evident in multiple cell lines, indicating that these apparently distinct signalling pathways may share a common convergence point downstream in the apoptotic cascade. 205, [211] [212] [213] 
Fas and p53
Fas/FasL up-regulation and sensitivity to Fas-induced death may depend on the presence of functional p53. 198 This observation may explain the non-participation of the Fas system in studies where the cell lines employed were p53 null or p53 negligible. 205 Lack of functional p53 may explain cellular inability to up-regulate Fas and FasL following drug treatment, indicating that there exists alternative pathways by which chemotherapeutic drugs mediate their cytotoxic effects.
Fas and survival signals
The relationships between the instructive death signal from Fas and survival signals are incompletely elucidated, but most studies, to date, indicate that survival pathways negatively regulate Fas-induced apoptosis. Oncogenic Ras suppresses Fas-mediated apoptosis by down-regulating Fas expression. 214 Indeed, Ras transformed cells have enhanced resistance to Fas-induced death. 215 Fas-induced apoptosis is counteracted by PI3-kinase signalling, in a PKB-dependent manner. 216 The tumour suppressor and PKB inactivator, PTEN, was found to sensitise glioma cells to Fas-but not chemotherapeutic drug-induced apoptosis. 217 Inhibition of PKC also promotes sensitivity to Fas-mediated apoptosis. 218 Thus, sensitivity to Fas-induced apoptosis may be dependent on the state of activation of intracellular survival and death pathways, where Fas-mediated death may be potentiated by inhibition of survival pathways such as PI3-kinase, 216 or activation of a death pathway, such as JNK.
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Such signal-specific targeting may prove to be of consequence in increasing sensitivity to both Fas-and cytotoxin-mediated apoptosis, with potentially immense implications for combination therapies.
Discussion
Drug resistance has previously been attributed to modifications in drug transport, metabolism and cellular repair. It is now increasingly evident that exploitation of survival pathways also significantly contributes to chemoresistance. Indeed, haematopoietic cytokines inhibit apoptosis induced by a range of cytotoxins, 219 presumably by activation of downstream survival pathways. Therefore, drug resistance appears to be multi-factorial, where several anti-apoptotic mechanisms are recruited to equip the cell with an increased survival capacity in order to facilitate disease progression and evade drug-induced apoptosis. 220, 221 The development of oncogenic lesions, where the capacity to promote apoptosis but not proliferation is abrogated, must be accompanied by anti-apoptotic aberrations in order to achieve malignancy. Bcl-2 inhibits apoptotic death normally induced by c-myc 222 and Ras co-operates with c-myc and p53 in cellular transformation. 223 Thus, secondary lesions or rescuing survival signals are essential to dissuade genetically unstable cells from automatically undergoing apoptosis. As such, therapies selective for Ras, Bcl-2 and other survival signals should be relatively specific for transformed cells.
Tumours possessing defects in their apoptotic pathway, may be considered, not so much drug resistant, as inherently resistant to death. Such defects are potentially more lethal than mechanisms which have developed in response to particular groups of cytotoxic agents, such as P-glycoprotein. As Ras dysfunction is a common activating lesion in leukaemias and other neoplasms, it is possible that Ras frequently provides the co-operating anti-apoptotic lesion, limiting the ability of cytotoxic drugs to engage cell death. Inhibitors of survival pathways would therefore significantly influence the cellular decision regarding life or death in the presence of chemotherapeutic drugs. In the absence of their obligatory survival signal, cells are pushed towards apoptosis with undoubtedly crucial consequences for chemotherapy (Figure 3) .
The clinical potential for protein kinase inhibitors is being increasingly recognised. Two therapies specific for Ras-transformed malignant cells include farnesyltransferase inhibitors and reoviral infection. These are currently showing promising results with low toxicity in clinical and preclinical trials, respectively. 35, 39 The c-Abl tyrosine kinase inhibitor, STI571, has been shown to inhibit Bcr-Abl-mediated transformation both in vitro and in vivo and is currently undergoing phase I clinical trials. 224, 225 PKC inhibitors under clinical evaluation include UCN-01 and PKC412. 226, 227 The PKC inhibitor LY333531 specifically targets PKC ␤ and has successfully demonstrated anti-tumorigenic activity in preclinical trials. 228 Although Bcl-2 antisense treatment has demonstrated significant anti-apoptotic effects, 229 the lack of a specific biochemical inhibitor is limiting clinical investigation. Likewise, no specific inhibitor of either PKB or JNK has been identified to date. A role for PI3-kinase in chemoresistance in vitro has only recently been reported 42, 59 and the potential (and toxicity) of the PI3-kinase inhibitors LY294002 and wortmannin have not yet been clinically evaluated.
Survival signals are unique in protecting cells by preventing the conversion of cytotoxin-induced injury into death signals. Survival signals, as their name suggests, increase the capacity of a cell to survive insult, possibly by allowing time for cell repair or the accumulation of anti-apoptotic lesions, thus promoting disease aggression and chemoresistance. An increased understanding of the molecular defects leading to overactive survival pathways, or suppression of apoptosis, could translate into a rational approach for the development of selective anticancer therapies, custom-made for individual malignancies. Specific inhibition of survival signals could reverse the intracellular decision towards survival, leading to increased apoptosis and tumour regression. An increased understanding of the tissue-specific requirements for survival and potential exploitation of cell-type specific pathways may yield new and more selective combination therapies, such as are already
Figure 3
The survival molecules Ras, PI3-kinase, PKB and PKC influence survival by at least two mechanisms: (1) by inhibiting the Fas-induced death cascade, and caspase activation; and (2) by cooperating with anti-apoptotic lesions such as Bcl-2. Both mechanisms limit the induction of apoptosis, enhance survival and contribute to chemoresistance.
Leukemia proving effective in the treatment of IL-6-dependent multiple myeloma. 230 In conclusion, despite considerable efforts, the problem of drug resistance remains largely unresolved. The significance of survival pathway signalling and co-operation with antiapoptotic processes, in addition to their inhibitory influence over death pathways and promoters of apoptosis, require better understanding before scientific progress may be converted into clinical advances.
